AstraZeneca PLC believes an emerging highly sensitive test for levels of troponin – proteins associated with heart damage – could help identify those who get the most benefit from treatment with its Brilinta, potentially improving the drug’s value proposition against generic clopidogrel.
FDA-approved since July 2011 for reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndromes, the novel...